Cosmos Pharmaceutical Corporation (TSE: 3349) reported consolidated FY5/2026 results under Japanese GAAP. Revenue rose 8.7% to ¥1,099,583 million; EBITDA rose 6.8% to ¥64,996 million; operating profit rose 4.8% to ¥42,353 million; ordinary profit rose 3.4% to ¥44,614 million; and net profit attributable to owners rose 3.4% to ¥32,046 million. Basic EPS was ¥404.33, up from ¥390.86.
Everyday-low-price model
Operating profit grew more slowly than revenue (+4.8% versus +8.7%), reflecting the chain's thin-margin "everyday low price" food-and-drug format and the up-front costs of opening new stores. The company remains one of Japan's largest drugstore operators by revenue, expanding from its Kyushu base across western and eastern Japan.
Balance sheet and investment
Total assets were ¥596,485 million and net assets ¥283,700 million, an equity ratio of 47.6%; book value per share was ¥3,579.49. Operating cash flow was ¥58,790 million, but an ¥81,903 million investing outflow — funded in part by a ¥19,315 million financing inflow — reflected the pace of new-store openings. Period-end cash stood at ¥53,241 million.
Dividend raised to ¥82
The FY5/2026 annual dividend rose to ¥82.00 per share (¥37.50 interim + ¥44.50 year-end) from ¥70.00, a payout ratio of 20.3%. Management guides ¥84.00 (¥42 + ¥42) for FY5/2027.
FY27 guidance
For FY5/2027 the company guides revenue of ¥1,190,000 million (+8.2%), operating profit of ¥43,000 million (+1.5%) and ordinary profit of ¥45,700 million (+2.4%), but net profit of ¥30,700 million (-4.2%), with EPS of ¥387.35, as cost pressure is expected to weigh on the bottom line.
| Metric | FY5/2026 | FY5/2025 | YoY |
|---|---|---|---|
| Revenue (¥ billion) | 1,099.58 | 1,011.39 | +8.7% |
| EBITDA (¥ billion) | 65.00 | 60.85 | +6.8% |
| Operating profit (¥ billion) | 42.35 | 40.40 | +4.8% |
| Ordinary profit (¥ billion) | 44.61 | 43.16 | +3.4% |
| Net profit attrib. to owners (¥ billion) | 32.05 | 30.98 | +3.4% |
| Basic EPS (¥) | 404.33 | 390.86 | +3.4% |
| Annual dividend (¥) | 82.00 | 70.00 | +17.1% |
| FY27 net profit guidance (¥ billion) | 30.70 | — | -4.2% |
JapanStockPulse provides informational content only and does not constitute investment advice. Figures are taken from the company's published earnings short report and may be subject to subsequent revision.